DelveInsight’s “Alzheimer’s disease (AD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Alzheimer’s disease (AD), historical and forecasted epidemiology as well as the Alzheimer’s disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Alzheimer’s disease market report provides current treatment practices, emerging drugs, Alzheimer’s disease market share of the individual therapies, current and forecasted Alzheimer’s disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alzheimer’s disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
A progressive disorder, Alzheimer’s disease leads to wasting off the brain cells and is one of the most common causes of dementia.
The DelveInsight Alzheimer’s disease market report gives a thorough understanding of the Alzheimer’s disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Click to know more about the report offerings: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
Alzheimer’s disease Epidemiology
The Alzheimer’s disease Epidemiology division provide insights about historical and current Alzheimer’s disease patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Alzheimer’s disease Market Outlook
The Alzheimer’s disease (AD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Alzheimer’s disease (AD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Alzheimer’s disease (AD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Alzheimer’s disease market in 7MM is expected to change in the study period 2017-2030.
Some of the key players in the therapeutic market of Alzheimer’s Disease (AD) at a global level are Neurotrope bioscience, Amarantus Bioscience Holdings, AgeneBio, Novartis, Cortexyme, TauRx Therapeutics, Otsuka Pharmaceutical, AC Immune, Genentech, Alkahest, AZ Therapies, Cerecin, vTv Therapeutics, and others.
The launch of potential emerging therapies, such as Bryostatin-1 (Neurotrope Bioscience), Eltoprazine (Amarantus Bioscience Holdings), AGB101 (AgeneBio), CAD106 and CNP520 (Novartis), COR388 HCL (Cortexyme), TRx0237 (TauRx Therapeutics), brexpiprazole (Otsuka Pharmaceutical), RO7105705 (Genentech/AC Immune), AKST/GRF6019 (Alkahest), ALZT-OP1 (AZ Therapies), Tricaprilin (Cerecin), Azeliragon (vTv Therapeutics), and others are expected to change the treatment landscape in the upcoming years.
Request for sample pages: https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market
Scope of the Report
- The report covers the descriptive overview of Alzheimer’s disease (AD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Alzheimer’s disease (AD) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Alzheimer’s disease (AD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Alzheimer’s disease (AD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alzheimer’s disease (AD) market
Table of Contents
1. Key Insights
2. Executive Summary of Alzheimer’s disease (AD)
3. Competitive Intelligence Analysis for Alzheimer’s disease (AD)
4. Alzheimer’s disease (AD): Market Overview at a Glance
5. Alzheimer’s disease (AD): Disease Background and Overview
6. Patient Journey
7. Alzheimer’s disease (AD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Alzheimer’s disease (AD) Treatment
11. Marketed Products
12. Emerging Therapies
13. Alzheimer’s disease (AD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Alzheimer’s disease (AD)
17. KOL Views
18. Market Drivers
19. Market Barriers
21. DelveInsight Capabilities
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States